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Peripheral artery disease (PAD), the narrowing of peripheral arteries located in areas such as the               
arms and legs, is a common disease that affects 12% to 20% of people over 65. Numerous                 
therapies have been developed to treat PAD, the most recent technology being drug-coated             
balloons. Drug-coated balloons release drugs, such as Paclitaxel (PTX), into the arterial wall             
during balloon angioplasty to locally treat PAD. Current levels of drug transfer from the balloon               
to the vascular endothelium are at a low 10%-18%. Our Biomedical Engineering Senior Design              
project aims to increase drug delivery of drug-coated balloons by manipulating the            
clinically-controllable variables of drug+excipient formulation, balloon inflation pressure, and         
balloon inflation time. To study the effects of these variable on drug transfer, we first developed                
in vitro models of the drug-coated balloon (PTX+Urea and PTX+Shellac formulations) and            
vascular endothelium (porcine blood vessels). These models were then subjected to uniaxial            
compression testing to simulate balloon inflation against the vessel wall at set inflation pressures              
and times. Our study found drug transfer to increase with increasing inflation pressure in the               
PTX+Urea formulation. In contrast, drug transfer for the PTX+Shellac formulation increased           
with inflation time. Though we were unable to increase drug transfer past 17%, our study               
indicates that manipulating the above clinical variables can be a powerful tool towards increasing              



































1. Problem definition: 
Peripheral artery disease (PAD) is defined as the narrowing of peripheral arteries located in parts               
of the body such as the arms, stomach, and most commonly, the legs. PAD is very common                 
among older adults and affects 12% to 20% of people over 65. The disease is usually caused by                  
atherosclerosis, the buildup of plaque in the wall of an artery. Plaque consists of fats,               
cholesterols, and other substances and can grow anywhere in an artery, restricting blood flow to               
a certain region. 
 
1.2 Peripheral artery disease treatment history: 
Minimally invasive treatment for PAD has evolved throughout the years. One of the first              
methods developed was percutaneous balloon angioplasty (Arjomand, et al., 2003). Still widely            
used today, this procedure involves inserting a balloon by catheter into the region of the artery                
consisting of plaque buildup. The balloon is then expanded; the expansion pushes the plaque into               
the wall of the artery, opening the affected region.  
In the 1980s, arterial stents became more prevalent with the first versions known as bare metal                
stents (BMS) (Arjomand, et al., 2003). The insertion procedure for BMSs is very similar to               
percutaneous balloon angioplasty; a balloon is inserted into the affected region via catheter and              
the balloon is expanded. The only difference is that a BMS is wrapped around the balloon and,                 
when expanded, the stent stays in place, holding the artery open and keeping the plaque pressed                
against the arterial wall. A major problem with bare metal stents is restenosis, the narrowing of                
the affected artery after stent implantation. BMSs have about a 30-40% restenosis rate with              
20-30% requiring reintervention (Mohan & Dhall, 2010). 
To resolve this issue, drug-eluting stents were developed in the early 2000s. These stents have               
polymer coatings that contain different types of drugs that deter cell proliferation (Arjomand, et              
al., 2003). The drugs function to drastically reduce the probability of restenosis in the affected               
area (2-3 %). Although drug-eluting stents have decreased restenosis, there are still other risks              
involved with polymer stents. Although rare, these stents pose a risk of late stent thrombosis, a                
threat posing a 45 % mortality rate (Pfisterer, 2008). 
A new method is needed to reduce the risks involved with polymers and BMS systems while                
maintaining the efficacy both have in PAD treatment. Drug-coated balloons are an emerging             
technology that follows the “leave nothing behind” strategy (Abramjuk, et al., 2004). These             
balloons release large amounts of drugs into the surrounding tissue, causing a structural change              
in the arterial wall.  
 
1.2 Drug delivery efficacy of drug-coated balloons: 
Since it is an emerging technology, many aspects must be investigated, such as the maintenance               
of the coating integrity during delivery, tissue toxicity due to rapid drug delivery, and adhesion               
to the wall of the artery. Perhaps most important to understand is the ability of this system to                  
transfer drugs from the balloon surface to the vascular endothelium. While a variety of              
drug-coated balloons continue to be developed, there is a need to increase the drug delivery               
efficacy of this system. Currently, drug transfer rates are approximately 10%-18% (Cremers, et             
al., 2017). Our team proposes a method to increase drug delivery efficacy of drug-coated              




variables of drug+excipient formulation, balloon inflation pressure, and balloon inflation time,           
we can enhance drug transfer to the vascular endothelium.  
 
2. Problem solution 
2.1 Identification of clinical factors affecting drug transfer 
There are a number of methods that have the potential to enhance drug transfer in drug-coated                
balloons. Our focus centers on variables that could be manipulated in the clinical setting. The               
physician performing an angioplasty procedure can affect drug transfer through (1) balloon            
material selection and the procedural variables of (2) inflation pressure and (3) inflation time.              
Our project proposes to study how these variables affect the drug transfer of Paclitaxel, an               
anti-cancer chemotherapy drug commonly used in drug-coated balloon technology. Paclitaxel          
(PTX) is a hydrophobic compound, making it a perfect drug for vascular drug delivery.              
Hydrophobic compounds bind to the wall of a vessel because they are insoluble in the aqueous                
environment found within the blood. It is also very effective in preventing proliferative vascular              
disease and is therefore used to induce antiproliferative activity in vessels (Creel, et al., 2000). 
 
2.1.1 Balloon material selection—excipients:  
Aspects of balloon selection can affect drug transfer in the way certain materials interact with the                
drugs. One such material, the excipient—combined with the drug to create the drug coating—can              
be chosen and controlled by the physician. Excipients are polymers that create a matrix with the                
drug as a way to hold it. They function to both retain the drug on the balloon surface as well as                     
carry it during homogenous transfer to the endothelium (Gongora, et al., 2015). Due to the               
varying molecular characteristics of different excipients, it is possible that certain excipients            
allow for higher adhesion and diffusion of drugs into the vasculature. For this reason, we will                
study how two commonly used excipients, Urea and Shellac, enhance the drug transfer of PTX.               
Urea is the most commonly used excipient in drug-coated balloon systems today and has been               
found to improve drug transfer by actively separating molecules of drug during transfer (Werk,              
et al., 2012). Shellac became a popular excipient choice because of its non-inflammatory nature,              
avoiding any detrimental effects to cell viability during drug transfer (Kirsten, et al., 2012).  
 
2.1.2 Procedural variable—balloon inflation pressure: 
During clinical procedures of angioplasty, the physician has control over the diameter of the              
balloon. The diameter of the balloon may also affect drug transfer, as a higher ratio of balloon to                  
vessel diameter would cause a higher pressure to be exerted on the vascular endothelium during               
inflation. Similarly, a higher inflation pressure would also increase the pressure exerted on the              
endothelium. These higher pressures might allow for the adhesion and transfer of greater             
amounts of drug. This project will therefore also study drug transfer as a function of varying                
balloon inflation pressures.  
 
2.1.3 Procedural variable—balloon inflation time: 
Lastly, a physician can manipulate the inflation time of the balloon. During inflation, blood flow               
is restricted. Therefore, inflation times during coronary angioplasty were traditionally limited to            
60 seconds in order to avoid compromising the viability of the cardiac tissue (Consigny &               
LeVeen, 1988). For application in PAD, these inflation times could be extended at the              




drug to the vascular through diffusion. This project will therefore also study drug transfer as a                
function of varying balloon inflation times. 
 
 
2.2 Proposed methodology 
In order to isolate and investigate the possible effects of the above stated clinical variables               
(excipient type, balloon inflation time, balloon inflation pressure) on drug delivery to the             
vascular endothelium, a uniaxial compression of arterial tissue with a simulated balloon was             
conducted. The simulated balloon was created as a linear piece using materials, drugs, and              
excipients that are commonly found in commercially available angioplasty balloons. Arterial           
tissue was harvested from porcine femoral arteries and mounted to a stationary block with the               
endothelium exposed. The simulated balloon was then displaced to compress the tissue at             
specified pressures and dwell times. With this testing scenario, the drug+excipient formulation,            
the balloon inflation pressure on endothelium, and the balloon inflation time can be             
independently studied without the confounding effects of blood flow and other real world             
procedural inconsistencies.  
 
2.3 Alternative solutions considered 
A variety of solutions can be tested in order to increase drug delivery efficacy of drug-coated                
balloons. Many studies have focused on altering the cylindrical design of the balloon structure              
while others have considered dual loading the drug coating with compounds that enhance drug              
retention (Xiong, et al., 2016). While these are important solutions that should be considered, our               
group is interested in enhancing drug transfer using clinical variables that are readily controlled              
in a procedural setting. Alterations such as balloon design would not be a factor that is controlled                 
by a physician, and were therefore discarded. In terms of methodology, an ​ex vivo ​, full vessel,                
balloon inflation testing procedure was considered. In this test, an extracted femoral artery would              
have been subject to the inflation of an angioplasty balloon at controlled inflation pressures and               
time. This testing procedure would have allowed for the investigation of the effects of a               
cylindrical geometry on the drug transfer but was ultimately discarded. In this scenario, it would               
have been impossible to control the exact pressure acting on the vascular endothelium and              
therefore the effect of this variable would not have been possible to calculate.  
 
3. Goal/Objectives: 
1. Goal 1: ​Investigate adhesion mechanics of drug delivery for the clinically-controlled           
variables of ​drug+excipient formulation, balloon inflation time, and balloon inflation          
pressure.  
a. Objective 1a ​. ​Create drug-coated balloon models with drug coat density of 
3 μg/mm​2​ and a drug:excipient ratio of 1:1.  
b. Objective 1b. ​Determine the yield stress of the adhesive boundary between the 
balloon coating and vascular endothelium in relation to balloon inflation time and 
inflation pressure between ranges of 30-180 s and 100-400 mm-Hg, respectively. 
2. Goal 2​: Optimize drug transfer conditions to vascular endothelium using the           
clinically-controlled variables of drug+excipient formulation, balloon inflation time, and         




a. Objective 2a. ​Determine the ranges of the above variables at which the greatest             
amount of drug is transferred to the endothelium.  
b. Objective 2b. ​Achieve drug transfer greater than current values to ≥ 20%. 
 
4. Methodology: 
Medicinal Mechanics proposes a series of methods to complete the stated goals and objectives.              
The supplies and instrumentation utilized for these methods is delineated in Table 1. All              
experiments were performed using ​in vitro ​models of drug-coated balloons (bearing various            
PTX+excipient formulations) and the vascular endothelium. These models were subjected to           
mechanical testing that simulates various balloon inflation pressures and inflation times. During            
these tests, effects of various pressures and times on the adhesive boundary between the drug               
coating and vascular endothelium were also measured; this was done by recording the failure              
load of the adhesive boundary. After mechanical testing, drug transfer resulting from various             
pressures and times was quantified. To do this, liquid chromatography tandem mass            
spectrometry (LC-MS/MS) was performed on PTX extracted from the vessel. 
 
Table 1. ​Medicinal Mechanics Project Budget. ​The table lists all budget and materials utilized in this                
project. Materials marked as (*) were provided by project sponsor and are therefore not considered in                
total cost calculation. Bolded materials were purchased using USC Biomedical Engineering Department            
funds.  
Material Price Material Justification 
Paclitaxel $206.92 Drug tested for delivery to the vascular endothelium 
Urea $44.20* Polymer that functions as an excipient to the drug 
Shellac $97.60* Polymer that functions as an excipient to the drug 
Porcine vessels $100* Porcine blood vessels were used to model the vascular endothelium 
Polyamide-Nylon 12 $193.91 A polyamide nylon sheet was used to model the balloon surface 
Polystyrene mounting 
blocks 
$200* Mounting blocks held the models during mechanical testing and 
attached to testing apparatus 
Ethanol $71.00* 
 
PTX and excipients were dissolved in ethanol to create a coating 
mixture 
SEM microscopy $50.00/hr* Microscopy was used to visualize distribution of PTX+excipient 
formulations on balloon models 
Methanol $49.10 Methanol was used for PTX extraction from vascular endothelium 
LC-MS/MS testing $10/sample* 
$460 




Contingency fund $10.00 Other unforeseen expenses were covered with this fund 
Total Material Cost $1,000  
 
 
4.1 ​In vitro​ models: 
A schematic of the ​in vitro models can be seen in Figure 1. The models were created on                  
polystyrene mounting blocks which were designed and 3D-printed. These mounting blocks serve            
as a base for the balloon and endothelium models. They are also fixtures that will attach to the                  











Figure 1: Schematic of ​In Vitro Models. Polystyrene mounting blocks function as bases for subsequent               
mechanical testing. Drug-coated balloons are modeled with a nylon sheet to imitate the surface material               
of the balloon. Drug coating is created as a mixture of PTX and excipient that is placed on the nylon                    
sheet. Vascular endothelium is modeled using sections of porcine femoral arteries with endothelial             
surface exposed. 
 
4.1.1 Drug-coated balloon model:  
4.1.1a Drug+excipient formulations ​: Drug-coated balloon models were created for Paclitaxel by           
combining it with two commonly-used excipients: Urea and Shellac. Together, these           
materials create two combinations: PTX+Urea and PTX+Shellac. These PTX+excipient         
formulations describe the two drug coatings tested for drug delivery efficacy.  
 
4.1.1b Creation of balloon models ​: The drug-coated balloon models were created on polystyrene             
mounting blocks. Polyamide-Nylon 12 sheets were first fixed to the mounting blocks to             
model the surface material of the balloon (Matsumoto, et al., 1993). Previously described             
drug+excipient formulations were created by dissolving the drug and excipient in           
solution to a desired concentration. PTX formulations were dissolved in ethanol. Drug            
density on the surface of the balloon model was 3 µg/mm​2 for each formulation, and the               
excipient was added with a 1:1 ratio, as based on currently available drug-coated balloon              
models (Alfonso et al., 2013). These formulations were deposited uniformly onto nylon            
sheets by micro-pipetting. The balloon models were dried at room temperature to allow             
for the evaporation of ethanol. 
 
4.1.1c Quality control of balloon models ​: While micro-pipetting is commonly used to apply drug              




characterize the distribution of the coating resulting from this technique. Microscopy was            
used to confirm the uniform distribution of the drug coating onto the balloon model.              
Scanning electron microscopy was used to visualize the surface and cross-section of the             
drug coating, using previously described methods (Anderson, et al., 2016). While surface            
images were used for qualitative assessment of coat topography, cross-sectional images           
were measured for uniform coat thickness across the model. To do this, thickness at five               
random points of the coat were measured by image morphometric analysis on the ImageJ              
Software. Thicknesses were quantified by pixel measures of length and compared to            
confirm thickness did not vary by more than 10 μm.  
 
 
4.1.2 Vascular endothelium model: 
The vascular endothelium model was created on polystyrene mounting blocks. Harvested porcine            
femoral arteries purchased from a local abattoir were placed in 1% PBS and stored at 4°C until                 
use. Mechanical testing was performed within six hours to maintain freshness. The adventitia             
and extraneous tissues were manually removed from the artery and a radial cut was made to                
create a flat surface. Circles of tissue (diameter = 5 mm) were punched out from the artery using                  
a biopsy tool. The circles were then fixed onto the mounting block, with the vascular               
endothelium exposed, using adhesive. The prepared models were submerged in PBS prior to             
mechanical testing to avoid drying.  
 
4.1.3 Limitations: 
Using ​in vitro models to complete the methods allows the advantage to control the tested               
variables, namely drug+excipient formulation, balloon inflation pressure, and balloon inflation          
time. However, an ​in vitro setting limits predictive extension of any conclusions to in vivo               
conditions. This is mainly due to an inability to replicate ​in vivo conditions such as blood flow                 
within the artery. The ​in vitro models will also exhibit different geometric properties from              
drug-coated balloons used during clinical treatment. The models are flat surfaces whereas true             
conditions would replicate the cylindrical shape of the balloon technology and vasculature.  
 
4.2 Mechanical testing: 
All mechanical testing was performed on the BOSE ElectroForce® testing instrument. The            
polystyrene mount blocks holding each model were fixed to the testing instrument (Figure 2a). A               
















Figure 2: Schematic for Mechanical Testing. ​(​A​) Uniaxial compression testing of ​in vitro models is               
performed on the BOSE ElectroForce® instrument by fixing mounting blocks to attachments. (​B​) Balloon              
model is compressed against endothelium model at specified force and for a specified time to imitate                
various balloon inflation pressures and balloon inflation times, respectively. 
 
4.2.1 Mechanical testing protocol 
Uniaxial compression tests were performed on the vascular endothelium for various balloon            
inflation pressures and inflation times (N = 4-8 per test). As a baseline control, a compression              
test was also performed on an uncoated balloon model. Inflation pressures were simulated by              
balloon models compressing against the endothelium at set inflation forces. Forces were later             
converted to pressures as a function of the area of the circular endothelial tissue. Inflation times                
were simulated by holding the balloon models against the endothelium for a set amount of dwell                
time. To imitate inflation times and pressures that would be used in physiological conditions,              
ranges were under 180 seconds (Djavidani, et al., 2002) and 400 mm-Hg (Fröbert, et al., 2013),               
respectively. The chosen values for inflation time were set in the system as dwell times of 30, 60,                  
and 120 s. The chosen values for inflation pressures were set in the system as load force values                 
of 1, 2, and 3 N. To investigate the yield stresses of the adhesive boundary for each of the                  
variables, the failure load for the boundary was recorded. This indicates the load at which the                
balloon model detaches—or yields—from the endothelium after performing the compression.  
 
4.2.2 Limitations: 
To maximize vessel materials and perform a large number of mechanical tests each week, a               
small area of vessel tissue was chosen for the endothelium model. Because of the smaller surface                
area, there is a potential that the mechanical testing is not sensitive. The adhesion boundary               
between the balloon and endothelium models is extremely small. This provides a complication             
for the failure load recordings because they are significantly affected by the area of the adhesive                
boundary. This boundary is much larger in clinical conditions, so values may not be as accurate                
as they could be if larger areas of tissue endothelium were used. To counteract any errors caused                 
by vessel size, technical replicates were between N = 4-8 for all mechanical testing and             
subsequent drug transfer quantifications. 
 
4.3 Drug transfer quantification: 
After mechanical testing, extent of drug transfer to the vascular endothelium was assessed. This              
determined how drug delivery efficacy changes as a function of excipient type, balloon inflation              
pressure, and inflation time. Directly after mechanical testing, tissue was flash frozen and stored              
for future drug transfer quantification. For the quantification, PTX was first extracted from the              
endothelial tissue. This extracted drug was then sent for LC-MS/MS testing to quantify the              
amount of PTX residing in the endothelial tissue. To assess any significant differences in drug               
transfer across variable groups, 2-way ANOVA tests with Bonferroni posttests were performed            
for drug residing in the tissue after mechanical testing. 
 
4.3.1 Sample preparation – drug extraction: 
The stored endothelial samples were prepared for LC-MS/MS quantification by first extracting            




methanol and 0.1% acetic acid solution and then vortexed briefly. The tissue was then put in an                 
ultrasonic bath for 30 min. The bath was operating with conditions 200 W electric power at               
40 kHz with a temperature of 40°C. The samples were then centrifuged at 10000 x ​g for 10 min.               
The resulting supernatant, holding the extracted PTX, was transferred to a fresh Eppendorf tube              
and ready for LC-MS/MS analysis (Li, et al., 2017). 
 
4.3.2 Liquid chromatography tandem mass spectrometry: 
LC-MS/MS protocols for PTX (Buzzo, et al., 2018) have been previously described and were              
performed at the USC Mass Spectrometry Facility. A C18 column was used for the stationary               
phase. The mobile phase was made up of methanol and acetonitrile at a flow rate of 1.2 ml/min.                  
The LC system was coupled with triple quadrupole mass spectrometer for the quantification of              
PTX within the samples. Interpolation of PTX quantity in the unknown samples was done using               
a calibration curve created using known concentrations of PTX. The standard concentrations            
used were between 0.1-3 μg/mL In all experiments, the correlation coefficient for these curves             
were greater than 0.99. 
 
5. Results: 
Medicinal Mechanics has finished all mechanical testing with the PTX formulations (PTX+Urea            
and PTX+Shellac) as well as quantification of resulting drug transfer. To characterize the             
consistency of the balloon models created with these formulations, models were visualized using             
SEM. To assess how yield stresses of the adhesive boundary were affected by varying balloon               
inflation pressures and inflation times, failure load was recorded during mechanical testing.            
Lastly, drug transfer was quantified using LC-MS/MS analysis. 
 
5.1 Characterization of PTX balloon model: 
Cross-sectional and surface SEM images for the PTX+Urea and PTX+Shellac coated balloon            
models are shown in Figure 3 to assess quality control. Though only a qualitative measure, the                
surface images were utilized to confirm a consistent drug coating across the balloon model and               
visualize the microstructures of the coatings. The structures of the PTX+Urea and PTX+Shellac             
formulations can be clearly visualized and are distributed throughout the balloon surface. The             
thickness of the drug coating was measured using cross-sectional images. As much of this study               
deals with mechanical testing at the adhesive boundary, it is necessary to establish a consistent               
coating thickness that interacts with the vascular endothelium in a uniform manner. Multiple             
balloon models were not imaged to truly establish consistency in coating thickness; this makes it               
difficult to establish whether the models met the stated objectives. From preliminary images, the              
coating thickness was measured to be approximately 24.24 ± 12.70 µm for the PTX+Urea           
formulation and 40.34 ± 9.79 µm for PTX+Shellac.  
These coating values suggest coat thickness is highly variable for both models, indicating that              
the coating is not consistent. The differences between the PTX+Urea and PTX+Shellac            
coatings—both visually as well as in their respective thicknesses—furthermore indicate that           
these two excipients interact and combine with PTX in vastly different ways. The PTX+Urea              
coating creates a more crystalline structure whereas PTX+Shellac is much more spherical.            
LC-MS/MS was then used to quantify the PTX density on the balloon models prior to any                
mechanical testing, with a goal coating density of 3 μg/mm​2​. From LC-MS/MS analysis, coating             




density, this is still a realistic PTX density that is commonly found on commercially-available              
































Figure 3: SEM Images of Balloon Model. ​Cross-sectional and surface images of (​A​) PTX+Urea and (​B​)                
PTX+Shellac coated balloon models were taken using surface electron microscopy. Images were used to              
establish uniform coating of the drug formulations on the surface of the nylon sheet. Coat thickness was                 
approximately 24 μm for PTX+Urea and 40 μm for PTX+Shellac. Coating density on models was             
approximately 2.2 μg/mm​2​.  
 
5.2 Failure load of adhesive barrier 
The failure load of the adhesive boundary, created between the balloon coating and the vascular               
endothelium, at various loading scenarios is shown in Figure 4 for PTX+Urea and PTX+Shellac.              
For the PTX+Urea coating, there is a general trend present where increasing the inflation load               




significant at an inflation time of 60 s. It is hypothesized that an increased inflation load causes a                 
higher percentage of crystals within the drug coating to interact with the endothelium, causing              
the consequent increase in failure load. In contrast, there is no discernible trend in failure load for                 
the PTX+Shellac coating. For both PTX+Urea and PTX+Shellac there was no trend in failure              
load with respect to inflation time (data not shown). 
While it was originally believed that these two coating formulations would display similar trends              
in failure load, this difference is understandable. Urea and Shellac are two vastly different              
polymers that differentially crystalize with PTX, as evidenced by the SEM images provided             
above. These dissimilar crystalized coatings are then likely to interact with the adhesive             
boundary in two distinct manners. This is also indicated by the different magnitudes of failure               
load achieved by the two formulations. While certain loading scenarios in PTX+Urea yielded a              
failure load of 0.11 N (Fig. 4A), failure loads for PTX+Shellac were lower than 0.05 N (Fig. 4B).                  
Since PTX+Urea needs, in some cases, twice the force to yield from the endothelium, this data                
also suggests that PTX+Urea has a much stronger interaction with the endothelium than             
PTX+Shellac.  
Figure 4: Adhesive Failure Load for PTX+Urea and PTX+Shellac Coatings. ​Uniaxial compression            
tests were performed on porcine femoral arteries (N = 4-8) at varying inflations times (30, 60, 120 sec)                  
and inflation loads (1, 2, 3 N) to describe the adhesive failure of the balloon-endothelium boundary for the                  
PTX+Urea (​A​) and PTX+Shellac (​B​) coating formulations. All groups were compared by 2-way ANOVA              
using Bonferroni posttests (* ​P ​< 0.05, ** ​P​ < 0.01). 
 
5.3 Drug transfer of balloon models: 
Drug transfer for the PTX+Urea and PTX+Shellac formulation at various loading scenarios is             
shown in Figure 5. For both formulations, drug transfer changes with increasing inflation load.              
For PTX+Urea, drug transfer increases with inflation load (Fig. 5A) whereas the trend is flipped               
for PTX+Shellac (Fig. 5B). In contrast, PTX+Shellac yielded an increasing trend in drug transfer              
with respect to inflation time (Fig. 5D) while no such trend existed for the PTX+Urea               
formulation (Fig. 5C). It is readily apparent that there is vastly different magnitudes of PTX               
transfer in both formulations. A high PTX transfer of 16.9% was for PTX+Urea while transfer in                
PTX+Shellac was well below 1%.  
These results could once again be due to inherent differences between the two excipients.              




quality control testing was unable to be completed—there is a possibility that low drug transfer               
in PTX+Shellac may be due to poor balloon design. This possibility is furthermore supported by               
the large variance within the loading groups, clearly seen in the large error bars. This high                
variance not only dampens significant differences between loading scenarios but also indicates            
that the irregular drug transfer is due to inconsistent drug coating on the balloon models. The                
failure load data furthermore may indicate that the low drug transfer in PTX+Shellac may be due                
to the weak interaction this coating creates with the endothelium. Since the PTX+Shellac coating              
does not adhere as strongly to the endothelium as PTX+Urea, PTX has less of an opportunity to                 
transfer. Among these many possibilities, the data still strongly suggests that inflation pressure             
and inflation time play a significant role in drug transfer and can be manipulated to increase                









Figure 5: Drug Transfer for PTX+Urea and PTX+Shellac Coatings. ​After mechanical testing at             
varying inflations times (30, 60, 120 sec) and inflation loads (1, 2, 3 N), resulting drug transfer from the                   
PTX+Urea (A) and PTX+Shellac (B) coating formulations was quantified by LC-MS/MS. All groups             






Successful completion of this project was dependent on this team’s ability to complete the stated               
goals that investigated the effect of excipient type, inflation pressure, and inflation time on the               
adhesive boundary and, more importantly, drug transfer to the vascular endothelium. Completion            
of the aims will provide greater understanding on the mechanisms of drug transfer from              
drug-coated balloons and will also aid in the design of a more efficacious balloon technology               
with optimized clinical parameters. While there continue to be a number of limitations in this               
project that were discussed earlier in this report, important strides have been taken to improve the                
interventions and outcomes of PAD patients. 
The first goal of this project assesses the failure of the adhesive boundary created between the                
balloon coating and vascular endothelium. The values for failure—also known as yield            
stresses—allows for an improved design for balloon technologies by providing greater           
understanding on how excipient type, inflation pressure, and inflation time affect the adhesion             
between the coating and tissue. These values will also be used during an angioplasty operation,               
as the clinician must know the amount of force that is necessary to deflate the balloon and                 
remove it from the patient for successful completion of the operation. To complete this goal,               
drug-coated balloon models were first successfully created with a 1:1 drug:excipient ratio.            
However, drug density fell below 3.0 μg/mm​2 to be instead 2.2 μg/mm​2​. Furthermore,           
consistency of the model design couldn’t be confirmed using multiple SEM balloon images.              
Using these models, there was successful completion of the second stated objective to             
mechanically test the failure load at various inflation pressures and times. 
The second goal of this project investigates the effect of the clinical variables on drug transfer to                 
the endothelium and, ultimately, aims to increase drug transfer to 20% by optimizing these              
variables. Successful protocols for drug extraction and LC-MS/MS were previously created and            
experimentally tested for accuracy. As stated earlier, the two different formulations have resulted             
in very different values of drug transfer. The transfer for the PTX+Shellac formulation is less               
than 1% while there was a transfer of 16.9% for the PTX+Urea formulation. Although the               
second stated objective of exceeding 20% drug transfer was not achieved, transfer for the              
PTX+Urea formulation was within current values 10%-18% found in the literature. From this             
data, it can be conclusively confirmed that inflation pressure and time did affect drug transfer for                
PTX+Urea and PTX+Shellac, respectively. The first stated objective also looked to assess ranges             
of inflation pressure and inflation time that yielded the largest amount transfer, which were              
found to be at 3 N and 120 s, respectively. 
 
7. Future plans: 
Moving forward, Medicinal Mechanics’ immediate plan is to understand the reasons behind the             
minimal drug transfer seen in the PTX+Shellac formulation. As previously stated, current drug             
transfer rates are between 10%-18%. It was hypothesized that similar or greater drug transfer              
could be accomplished using this uniaxial balloon model because, compared to actual balloon             
angioplasty, there is no extraneous drug loss due to blood flow. This has not been the case for                  
PTX+Shellac, as drug transfer has been lower than 1%. In investigating this problem, one              
hypothesis is that the balloon model for PTX+Shellac has not been well-designed in terms of               
consistent drug coating. SEM images of balloon coats before and after mechanical testing are in               
the process of being collected from the uniaxial mechanical tests. Prior to analyzing these              




the cause of the minimal drug transfer has been identified and fixed, any changes in drug transfer                 
can be confidently related directly to increasing inflation pressure and time.  
Medicinal Mechanics has investigated the effects of excipient type, inflation pressure, and            
inflation time on PTX drug transfer in a simulated balloon angioplasty model. To further              
understand how drug transfer is modulated during balloon angioplasty, this project could be             
expanded to assess the effect of drug:excipient ratio. In all currently available drug-coated             
balloons, the ratio of excipient to drug is 1:1 (Schillinger, et al., 2002). Excipients are known to                 
increase drug transfer to the vascular endothelium by aiding in adhesion and diffusion (Radke, et               
al., 2011). The drug:excipient ratio could therefore likely affect—and even increase—drug           
transfer.  
In addition to affecting drug transfer, the variables of inflation pressure and inflation time may               
also influence other factors related to drug-coated balloon therapy and its efficacy. The cause of               
stenosis, intimal hyperplasia, is an inflammatory response that causes migration and proliferation            
of smooth muscle cells. At the same time, intervention with balloon angioplasty—including            
operations using drug-coated balloon technology—leads to an inflammatory response         
(Loh & Waksman, 2012). Treating an inflammatory disease with an intervention that causes          
inflammation is contradictory. Therefore, a future investigation into the inflammatory effects of            
inflation pressure and inflation time during balloon angioplasty can offer insight into factors that              
can reduce inflammation post-treatment.  
Verifying methods for improved drug transfer and reduced inflammation during drug-coated           
balloon angioplasty cannot be applied clinically unless these variables are shown to be effective              
at increasing efficacy. Therefore, once the effects of these variables on both drug transfer and               
inflammation have been investigated ​ex vivo ​, the next step would be to conduct ​in vivo               
experiments to confirm these effects in a three-dimensional model. These experiments will            
utilize a biaxial inflation of the drug-coated balloons against a cylindrical artery, ultimately             
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